BDBM168331 US9669031, 164 8′-chloro-1′,5′-dioxo-6′-(pyrimidin-4-ylamino)-1′,5′-dihydro-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-4-carbonitrile (Cpd. No. 164)
SMILES: Clc1cc(Nc2ccncn2)c(=O)n2c1C(=O)NC21CCN(CC1)C#N
InChI Key: InChIKey=GKABENCNXKROOG-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MAP kinase-interacting serine/threonine-protein kinase 2 (Homo sapiens (Human)) | BDBM168331 (US9669031, 164 8′-chloro-1′,5′-d...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | 25 |
eFFECTOR THERAPEUTICS, INC. US Patent | Assay Description Compounds are screened for Mnk inhibition using the ADP-Glo kinase assay kit (Promega, catalogue No. V9101). All kinase reactions are performed in Re... | US Patent US9669031 (2017) BindingDB Entry DOI: 10.7270/Q26Q1VDT | |||||||||||
More data for this Ligand-Target Pair |